Skip to main content
    O

    OUTLOOK THERAPEUTICS INC (OTLK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.40
    -0.02 (-4.12%)

    Market Cap: $100.54M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    OUTLOOK THERAPEUTICS INC (OTLK) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2026. Financial statements from company filings, amounts in US dollars.

    OUTLOOK THERAPEUTICS INC reported revenue of $1.41M for the fiscal year ended Sep 30, 2025, up 730.9% from the year before. That year, net income was -$62.42M with a net margin of -4416.2%, operating cash flow was -$51.83M and free cash flow was -$51.83M. The quarter ended Jun 30, 2026 had revenue of $9.00K and net income of -$20.32M.

    Revenue and Margins

    Over the 9 years to Sep 2025, revenue fell from $2.98M, a compound annual decline of 8.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$1.41M+730.9%46.5%-4744.3%-4416.2%
    Sep 2024$170.12KN/A-66.9%-42147.6%-44301.0%
    Sep 2023$0N/AN/AN/AN/A
    Sep 2022$0N/AN/AN/AN/A
    Sep 2021$0-100.0%N/AN/AN/A
    Sep 2020$5.85M-28.1%-9.5%-597.4%-602.0%
    Sep 2019$8.15M+163.8%-192.2%-445.6%-423.8%
    Sep 2018$3.09M-19.0%99.4%-960.0%-974.5%
    Sep 2017$3.81M+27.9%99.4%-941.2%-1019.1%
    Sep 2016$2.98MN/A98.9%-1723.1%-1788.7%
    Annual, fiscal years ended Sep 2016 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Revenue$1.41M$170.12K$0$0$0$5.85M$8.15M$3.09M$3.81M$2.98M
    Cost of revenue$756.33K$113.86K$44.19K$204.69K$262.14K$554.07K$23.80M$18.50M$23.81M$32.76K
    Gross profit$657.21K-$113.86K-$44.19K-$204.69K-$262.14K-$554.07K-$15.66M$3.07M$3.79M$2.95M
    Research and development$27.78M$41.76M$26.45M$42.33M$38.96M$26.34M$23.80M$18.50M$23.81M$32.76M
    Operating income-$67.06M-$71.70M-$53.13M-$63.07M-$51.73M-$34.97M-$36.30M-$29.64M-$35.88M-$51.35M
    Net income-$62.42M-$75.37M-$58.98M-$66.05M-$53.16M-$35.24M-$34.52M-$30.09M-$38.85M-$53.30M
    EBITDA-$63.58MN/AN/AN/AN/A-$34.42M-$31.11M-$26.79M-$30.03M-$48.95M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$9.00K$127.44K-$1.21M-$91.79K$1.51M$0$170.12K$170.12K$0$0$0$0
    Gross profit-$8.00K-$21.89K-$1.24M-$1.01M$1.07M-$29.10K-$28.80K-$28.80K-$28.67K-$28.20K-$28.20K-$11.22K
    Operating income-$10.81M-$14.03M-$13.48M-$17.31M-$15.75M-$12.39M-$21.61M-$22.88M-$19.56M-$18.94M-$10.32M-$12.46M
    Net income-$20.32M-$4.45M-$23.06M-$13.29M-$20.15M-$46.36M$17.38M$5.69M$44.41M-$114.29M-$11.18M-$12.99M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, short-term debt of $30.01M exceeded cash and equivalents by $21.92M. Shareholder equity was negative, at -$32.19M, as total liabilities of $50.77M exceeded total assets of $18.58M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Total assets$18.58M$28.82M$32.30M$28.53M$22.81M$19.73M$17.13M$22.28M$20.73M$23.71M
    Current assets$17.39M$27.42M$30.98M$27.52M$21.51M$17.94M$13.50M$3.30M$3.90M$5.68M
    Cash and equivalents$8.08M$14.93M$23.39M$17.40M$14.48M$12.54M$8.02M$1.72M$3.19M$2.35M
    Total liabilities$50.77M$101.90M$46.74M$19.79M$18.20M$16.91M$27.90M$43.09M$51.46M$28.91M
    Short-term debt$30.01M$29.49M$35.56M$10.95M$973.52K$7.85M$11.53M$18.38M$5.01M$6.18M
    Long-term debtN/AN/AN/AN/A$10.89M$904.20K$50.28K$98.49K$13.38M$2.23M
    Shareholder equity-$32.19M-$73.08M-$14.44M$8.74M$4.61M$2.83M-$10.77M-$20.81M-$30.73M-$5.20M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$26.18M$21.89M$18.24M$18.58M$22.39M$19.08M$17.01M$28.82M$47.09M$59.03M$21.68M$32.30M
    Total liabilities$36.58M$50.89M$56.79M$50.77M$59.58M$51.54M$67.30M$101.90M$130.77M$193.26M$46.03M$46.74M
    Cash and equivalents$11.24M$7.75M$8.68M$8.08M$8.90M$7.56M$5.70M$14.93M$32.02M$47.23M$10.36M$23.39M
    Shareholder equity-$10.39M-$28.99M-$38.55M-$32.19M-$37.19M-$32.46M-$50.29M-$73.08M-$83.67M-$134.24M-$24.34M-$14.44M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Operating cash flow-$51.83M-$68.79M-$42.97M-$56.67M-$54.25M-$31.79M-$32.29M-$33.04M-$15.51M-$45.48M
    Capital expenditures$3$0$2$0$0$3$437.31K$2.78M$292.09K$1.10M
    Free cash flow-$51.83M-$68.79M-$42.97M-$56.67M-$54.25M-$31.79M-$32.73M-$35.82M-$15.80M-$46.58M
    Dividends paidN/AN/AN/AN/AN/A$166.13B$624.99B$1.89T$16.98BN/A
    Investing cash flowN/AN/AN/AN/AN/A-$900.00K-$437.31K-$2.78M-$292.09K-$1.10M
    Financing cash flow$44.98M$60.33M$48.97M$59.59M$56.19M$37.21M$39.03M$34.35M$16.63M$39.86M
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$21.99M-$7.83M-$14.94M-$12.38M-$11.90M-$16.58M-$10.97M-$16.98M-$19.51M-$19.27M-$13.03M-$12.74M
    Capital expenditures$0$0$0$0$0$3$5$3$3$3$0$4
    Free cash flow-$21.99M-$7.83M-$14.94M-$12.38M-$11.90M-$16.58M-$10.97M-$16.98M-$19.51M-$19.27M-$13.03M-$12.74M
    Last 12 quarters

    Frequently Asked Questions About OTLK

    What is OUTLOOK THERAPEUTICS INC's annual revenue?

    OUTLOOK THERAPEUTICS INC reported revenue of $1.41M for the fiscal year ended Sep 30, 2025.

    How fast is OUTLOOK THERAPEUTICS INC's revenue growing?

    Revenue was up 730.9% for the fiscal year ended Sep 30, 2025 compared with the year before.

    Is OUTLOOK THERAPEUTICS INC profitable?

    No. OUTLOOK THERAPEUTICS INC reported net income of -$62.42M for the fiscal year ended Sep 30, 2025, with a net margin of -4416.2%.

    How much free cash flow does OTLK generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$51.83M minus capital expenditures of $3 produced free cash flow of -$51.83M.

    How much debt does OUTLOOK THERAPEUTICS INC have?

    The balance sheet dated Sep 30, 2025 reported short-term debt of $30.01M and cash and equivalents of $8.08M.